J&J faces patent challenges and competitive pressure from biosimilars launched by Amgen and Teva, compounded by new price setting requirements under the Inflation Reduction Act.

The entities involved

• Johnson & Johnson →

  U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer

  • P&G, Johnson & Johnson, and Coca-Cola are noted as dividend growth stocks, coinciding with SEC requirements for fiduciaries to prioritize interests.Mon 00:50
  • Johnson & Johnson separated its Consumer Health business into Kenvue on August 25, 2025.Sun 04:04
• Amgen →

  American multinational biopharmaceutical company

  • Amgen, City of Hope, and the California Community Foundation are involved in a life sciences and bioscience economic summit held in Downtown Los Angeles.Mon 12:08
  • Geode Capital Management increased its stake in Amgen stock and filed the disclosure with the SEC.Mon 02:05
• Teva Pharmaceutical Industries Ltd. →

  Israeli pharmaceutical company

  • Teva Pharmaceutical Industries Ltd. is being investigated by the Competition Authority regarding generic competition practices.Mon 13:16
  • Leerink partners issued an 'outperform' rating on Teva stock, while an insider sold shares of the company.Wed 01:19

Related events

• JNJ secured marketing authorization from the U.S. FDA, and its Ottava platform challenges ISRG's market dominance.Jul 24
• Pfizer, Johnson & Johnson, and Merck are facing significant industry pressures due to patent cliffs and market pricing demands.Wed 15:27
• Medical device sales are up in the U.S., but major players like J&J are facing market headwinds due to the VBP program in China.Jun 7
• Johnson & Johnson highlighted growth opportunities within the MedTech sector.Sep 10
• Johnson & Johnson is reportedly considering a sale of its orthopedics business unit within DePuy Synthes.Sep 15